List/Grid

Tag Archives: Virus

Target for treating dengue fever discovered

Target for treating dengue fever discovered

Two recent papers by a University of Colorado School of Medicine researcher and colleagues may help scientists develop treatments or vaccines for Dengue fever, West Nile virus, Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. Jeffrey S. Continue reading

Novel stapled peptide nanoparticle combination prevents RSV infection, study finds

Novel stapled peptide nanoparticle combination prevents RSV infection, study finds

New therapies are needed to prevent and treat respiratory syncytial virus (RSV) — a potentially lethal respiratory infection that can severely affect infants, young children and the elderly. Despite a wide range of anti-RSV efforts, there are no vaccines or drugs on the market to effectively prevent or treat the infection. Now researchers at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Harvard Medical School in Boston, MA, and the James A. Continue reading

HIV-positive women respond well to HPV vaccine, study shows

HIV-positive women respond well to HPV vaccine, study shows

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. Continue reading

New combination drug therapy proves very effective in hepatitis C treatments

New combination drug therapy proves very effective in hepatitis C treatments

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy Continue reading

New combination drug therapy proves very effective in hepatitis C treatments

New combination drug therapy proves very effective in hepatitis C treatments

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy Continue reading

New Chinese herbal medicine has significant potential in treating hepatitis C, study suggests

New Chinese herbal medicine has significant potential in treating hepatitis C, study suggests

ata from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus’ lifecycle.i SBEL1 is a compound isolated from Chinese herbal medicines that was found to inhibit HCV activity by approximately 90%. SBEL1 is extracted from a herb found in certain regions of Taiwan and Southern China. Continue reading

Viral hepatitis more deadly than HIV in Europe

Viral hepatitis more deadly than HIV in Europe

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014. Continue reading

Guinea ‘Ebola deaths pass 100′

Guinea ‘Ebola deaths pass 100′

unable to retrieve full-text contentThe Ebola outbreak could take up to four months to contain as the number of people killed by the virus in Guinea passes 100, the UN says. Continue reading

Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven

Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. Continue reading

Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven

Rilpivirine combination product in pretreated HIV-1 patients: Added benefit not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment. Continue reading